AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 09 2021 - 3:05PM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company developing first-in-class antibody product candidates
focused on emerging immune control mechanisms applicable to
inflammation and immuno-oncology indications, today announced that
Hamza Suria, chief executive officer of AnaptysBio, will present an
overview of AnaptysBio at the H.C. Wainwright 23rd Annual Global
Investment Conference. The presentation will be available on Monday
September 13, 2021, at 7:00 a.m. ET via:
https://journey.ct.events/view/9ece1408-084b-41dd-9e6e-8977a5086047
A webcast of the presentation will also be
available through the investor section of the AnaptysBio website at
https://ir.anaptysbio.com/events. A replay of the webcast will be
available for 90 days following the event.
About AnaptysBio
AnaptysBio is a clinical-stage biotechnology
company developing first-in-class antibody product candidates
focused on unmet medical needs in inflammation. The Company’s
proprietary anti-inflammatory pipeline includes imsidolimab, its
anti-IL-36R antibody, previously referred to as ANB019, for the
treatment of dermatological inflammatory diseases, including
generalized pustular psoriasis, or GPP, acne, hidradenitis
suppurativa, EGFRi skin toxicity and ichthyosis; rosnilimab, its
anti-PD-1 agonist program, previously referred to as ANB030, for
treatment of certain autoimmune diseases where immune checkpoint
receptors are insufficiently activated; and its BTLA modulator
program, ANB032, which is broadly applicable to human inflammatory
diseases associated with lymphoid and myeloid immune cell
dysregulation. AnaptysBio’s antibody pipeline has been developed
using its proprietary somatic hypermutation, or SHM platform, which
uses in vitro SHM for antibody discovery and is designed to
replicate key features of the human immune system to overcome the
limitations of competing antibody discovery
technologies. AnaptysBio has also developed multiple
therapeutic antibodies in an immuno-oncology collaboration with
GSK, including an anti-PD-1 antagonist antibody (JEMPERLI
(dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab,
GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386), and
an inflammation collaboration with Bristol-Myers Squibb, including
an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in
clinical development.
Contact:Dennis MulroyAnaptysBio,
Inc.858.732.0201dmulroy@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jun 2024 to Jul 2024
AnaptysBio (NASDAQ:ANAB)
Historical Stock Chart
From Jul 2023 to Jul 2024